MW
CJC-1295 (no DAC): 1,211.4 g/mol · Ipamorelin: 711.9 g/mol
Purity
>99%
Growth Hormone Axis
CJC-1295 / IPAMORELIN
GHRH / GHRP Synergy Blend
Synthetic GHRH analog (Modified GRF 1-29, without Drug Affinity Complex) combined with a synthetic pentapeptide growth hormone secretagogue
$125
Per vial · Research use only · COA available
Compound Profile
| Appearance | Lyophilized white powder |
| Molecular Weight | CJC-1295 (no DAC): 1,211.4 g/mol · Ipamorelin: 711.9 g/mol |
| Amino Acids | 29 (CJC-1295, no DAC) + 5 (Ipamorelin) |
| Dosage | 10 mg + 10 mg |
| Volume | 3 mL |
| Solubility | Bacteriostatic water |
| Purity | ≥98% (HPLC-UV-MS verified) |
| Storage | −20°C long-term · 4°C short-term · Protect from light |
Amino Acid Sequence
CJC-1295 (no DAC): Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg · Ipamorelin: Aib-His-DTrp-Ala-Trp-DPhe-Lys-NH2
COA, sterility, endotoxin, and heavy metal test results available upon request.
For Research Use Only. This product is not for human consumption, clinical use, or veterinary use. Must be 21+ to purchase. Not evaluated or approved by the FDA for any therapeutic use. Introduction into humans or animals is strictly prohibited by law.
Overview
About CJC-1295 / IPAMORELIN
CJC-1295 without DAC (also known as Modified GRF 1-29) is a growth-hormone-releasing hormone (GHRH) analog studied for its ability to stimulate pulsatile GH release from the pituitary. Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor and is studied for a comparatively 'clean' hormonal profile, with minimal reported impact on cortisol, prolactin, or aldosterone relative to older GHRPs. The two are frequently studied together because they act on distinct but complementary GH-release pathways — the GHRH receptor and the ghrelin/GHS receptor — producing an additive pulsatile GH-release profile in preclinical models.
Mechanism of Action
How It Works
CJC-1295 (no DAC) binds the GHRH receptor on pituitary somatotrophs, increasing cAMP signaling and triggering GH synthesis and secretion. Its short half-life relative to the DAC-conjugated version preserves the pulsatile character of natural GH release rather than producing sustained elevation. Ipamorelin binds the ghrelin/GHS-R1a receptor, amplifying GH pulse amplitude with high receptor selectivity. Research models combining both compounds report a synergistic increase in GH pulse amplitude and frequency beyond either compound studied alone.
Scientific Literature
Research Highlights
Dual-pathway GH stimulation — GHRH receptor plus ghrelin/GHS-R1a receptor activation
Preserved pulsatile GH release pattern — distinct from sustained-release GHRH analogs
Ipamorelin studied for high selectivity — minimal cortisol, prolactin, and aldosterone shift
Synergistic GH pulse amplitude in combination models versus either peptide alone
IGF-1 elevation studied downstream of pituitary GH release
Research interest in lean mass, recovery, and sleep-architecture study models
Commonly studied as a foundational GH-secretagogue stack in peptide research
Research Disclaimer: All research highlights are derived from published preclinical, in vitro, and animal studies. Results observed in laboratory models may not translate to human outcomes. Genfinite makes no claims regarding therapeutic efficacy. All products are sold strictly for scientific research purposes only.
Handling
Storage & Reconstitution
Dry Storage
Store lyophilized powder at −20°C, away from light and moisture. Do not open until ready to use. Shelf life is significantly extended by proper dry storage.
Reconstitution
Reconstitute using Bacteriostatic water. Add solvent slowly to the side of the vial and allow to dissolve gently. Do not shake vigorously.
Post-Reconstitution
Store reconstituted solution refrigerated at 4°C. Use within your laboratory's established timeframe. Do not refreeze after reconstitution.
